Surgical science Sweden WKN: A2P46G ISIN: SE0014428512 Forum: Aktien User: DrGreenthumb

Läuft einfach gut.... https://surgicalscience.com/aktien/financial-reports/ Net sales amounted to SEK 95.3 million (24.9), cor- responding to an increase of 282 percent compared with the corresponding period in the preceding year. Simbionix is included in the amount of SEK 50.3 million. ■ For comparable units, sales increased by 31 percent. ■ Operating profit amounted to SEK 7.6 million (7.3). The outcome includes acquisition costs of SEK 21.8 million. ■ Net profit amounted to SEK 14.4 million (5.9), corres- ponding to earnings per share of SEK 0.33 (0.17). ■ Cash flow from operating activities amounted to SEK 51.6 million (9.2). As of September 30, 2021, cash and cash equivalents amounted to SEK 310.6 million (74.7). ■ On July 28, it was announced that Surgical Science had entered into an agreement to acquire Simbionix. See also Note 6 on page 17. On August 16, an Extraordinary General Meeting was held, at which the directed share issue to finance the acquisition was approved. The transfer of ownership took place on August 24, and Simbionix is consolidated from that date.